Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Licensing Opportunity and/or Cooperative Research and Development Agreement (``CRADA'') Opportunity: Drug and Method for the Therapeutic Treatment of Ovarian Cancer and Mesotheliomas Respondees interested in licensing the invention(s) will be required to submit an ``Application for License to Public Health Service Inventions'' on or before September 21, 1998 for priority consideration.
View Prospective Grant of Exclusive License: Noncompetitive Antagonists of Dopamine Reuptake Inhibitors To Treat Drug Addiction Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 27, 1998 will be considered.
View Prospective Grant of Exclusive License: Container for Drying Biological Samples, Method of Making Such Container, and Method of Using Same Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 6, 1998 will be considered.
View National Cancer Institute: VHL and MET Mutation Detection Technology: Opportunities for Cooperative Research and Development Agreements (CRADAs) for the Joint Evaluation and Development of Methods to Detect Mutation in Both Gene Sequences Using Nucleic Acid Array Technology Inquiries regarding licensing and scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably one page or less, must be submitted to NCI on or before July 6, 1998. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents who have been selected. SUPPLEMENTARY INFORMATION:
View Prospective Grant of Exclusive License: Highly Informative Microsatellite Repeat Polymorphic DNA Markers Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 6, 1998, will be considered.
View Prospective Grant of Exclusive License: Use of Short WAP Promoter in Mammary Tissue of Transgenic Animals Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 26, 1998 will be considered.
View Prospective Grant of Exclusive License: Use of Short WAP Promoter in Mammary Tissue of Transgenic Animals Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 26, 1998 will be considered.
View Prospective Grant of Exclusive License: Use of Long WAP Promoter in Mammary Tissue of Transgenic Animals Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 26, 1998 will be considered.
View Prospective Grant of Exclusive License: Use of Long WAP Promoter in Mammary Tissue of Transgenic Animals Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 26, 1998 will be considered.
View Prospective Grant of Exclusive License: Spectroscopic Imaging Device Employing Imaging Quality Spectral Filters Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 26, 1998 will be considered.
View National Institute on Deafness and Other Communication Disorders (NIDCD); Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of a Vaccine Against Moraxella Catarrhalis Mediated Otitis Media
View Comprehensive List of Current Guidance Documents at the Food and Drug Administration General comments on this list and on agency guidance documents are welcome at any time.
View Prospective Grant of Exclusive License: Method of Determining the Presence of Functional p53 in Mammalian Cells Only written comments and/or applications for a license which are received by NIH on or before May 11, 1998 will be considered.
View Prospective Grant of Exclusive License: Dynamically Stable Associative Learning Neural Network System Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 9, 1998 will be considered.
View Prospective Grant of Exclusive License: Pharmaceutical Compositions And Methods For Treatment of Hyperproliferative Epithelial Skin Diseases and Cancer Only written comments and/or applications for a license which are received by NIH on or before March 23, 1998 will be considered.
View Prospective Grant of Exclusive License: Promotion of Homologous Recombination DNA Pairing by RecA And RecA Peptides Only written comments and/or applications for a license which are received by NIH on or before February 10, 1998 will be considered.
View Prospective Grant of Exclusive License: Therapeutic Uses of Blood Vessel Growth Promoting Peptides Including Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF) for Cardiovascular Disease and Conditions Such as Myocardial Ischemia Only written comments and/or applications for a license which are received by NIH on or before February 9, 1998 will be considered.
View National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Transgenic Mice That Express Human Cytochrome P450 Genes In view of the important priority of developing new drugs for the treatment of cancer and methods for determining carcinogenic risk, interested parties should notify this office in writing not later that January 2, 1998. Respondents will then be provided an additional 30 days for filing of formal proposals.
View Prospective Grant of Exclusive License: Pigment Epithelium Derived Growth Factor Only written comments and/or applications for a license which are received by NIH on or before January 26, 1998 will be considered.
View Prospective Grant of Exclusive License: Immunodampening Technology Only written comments and/or applications for a license which are received by NIH on or before February 17, 1998 will be considered.
View Prospective Grant of Exclusive License: IL-4 Pseudomonas Exotoxin Fusion Protein Therapeutics Only written comments and/or applications for a license which are received by NIH on or before January 26, 1998 will be considered.
View Prospective Grant of Exclusive License: Synthetic, Anti- Complement Protein and Gene Useful in Transplant Therapeutics Only written comments and/or applications for a license which are received by NIH on or before December 26, 1997 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Limited Exclusive License: Monoclonal Antibodies to Thymidylate Synthase Only written comments and/or applications for a license which are received by NIH on or before November 18, 1997 will be considered.
View National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADAs) for the Development of New Targeted Drugs, Made Partly of Entities Provided by the National Cancer Institute (NCI), as Treatments for Patients With Cancer Organizations must submit a confidential proposal summary preferably one page or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.